ImmunityBio, Inc. is a biotech company developing new medicines.
ImmunityBio, Inc. (IBRX) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 07:34 ET. Consensus EPS estimate is $-0.08.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | FY2026 Q2 | $-0.08 | $-0.22 | -175.0% | $51.24M |
| 2026-02-23 | FY2025 Q4 | $-0.08 | $-0.06 | +21.7% | $38.28M |
| 2025-11-05 | FY2025 Q3 | $-0.10 | $-0.07 | +29.0% | $32.06M |
| 2025-08-05 | FY2025 Q2 | $-0.10 | $-0.10 | +0.0% | $26.43M |
| 2025-05-12 | FY2025 Q1 | $-0.12 | $-0.15 | -25.0% | $16.52M |
| 2024-11-12 | FY2024 Q3 | $-0.18 | $-0.12 | +33.3% | $6.11M |
| 2024-08-12 | FY2024 Q2 | $-0.17 | $-0.20 | -17.6% | $1.05M |
| 2024-05-09 | FY2024 Q1 | $-0.16 | $-0.20 | -25.0% | $40.00K |
IBRX has beaten consensus EPS in 4 of its last 8 reported quarters.
IBRX reported Aug 4. The highlights: EPS of -$0.22 — a sharp miss vs the -$0.08 estimate (-175%); revenue of $51M — a beat vs the $50M consensus (+3%).
See IBRX on the live calendar →